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O B J E C T I V E S This study evaluated the usefulness of fasting 18F-ﬂuorodeoxyglucose (FDG)–
positron emission tomography (PET) in the diagnosis and management of cardiac sarcoidosis (CS) and
compared it with FDG uptake in dilated cardiomyopathy (DCM).
B A C KG ROUND Cardiac sarcoidosis may clinically present as DCM but is amenable to systemic
corticosteroid therapy if disease activity is high. Although alterations of FDG uptake have been reported
in CS, limited information is available on the quantitative estimates of FDG uptake.
METHOD S Fasting FDG–PET was performed in 24 systemic sarcoidosis patients and was compared
with 8 age-matched DCM patients. FDG–PET was also performed in 15 age-matched healthy control
subjects. Twelve of the 24 sarcoidosis patients had cardiac involvement based on criteria established by
the Japanese Ministry of Health and Welfare; the remaining 12 of 24 patients revealed no evidence of
cardiac involvement. The myocardial FDG uptake was quantiﬁed by measuring the standardized uptake
value in 17 myocardial segments in each subject. Coefﬁcient of variation (COV), which equals the
standard deviation of uptake divided by the average uptake of 17 segments, was calculated as an index
of heterogeneity in the heart.
R E S U L T S The FDG uptake was distinctly heterogeneous in CS patients. The COV value was
signiﬁcantly greater in CS patients (0.25 0.05) than control subjects (0.14 0.03, p 0.01), sarcoidosis
patients without cardiac involvement (0.14  0.03, p  0.01), or DCM patients (0.15  0.02, p  0.01).
The COV value in DCM patients was similar to control subjects or sarcoidosis patients without cardiac
involvement. The cutoff COV value for the diagnosis of CS was 0.18 (sensitivity: 100%; speciﬁcity: 97%).
After corticosteroid therapy in CS patients, the COV value was decreased to 0.14  0.06 (p  0.05) and
became essentially similar to the other groups.
CONC L U S I O N S Heterogeneous myocardial FDG uptake may be a useful diagnostic marker of
disease activity for CS. (J Am Coll Cardiol Img 2010;3:1219–28) © 2010 by the American College of
Cardiology Foundation
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1220arcoidosis is a multisystem disorder of un-
known etiology, characterized by the forma-
tion of noncaseating epithelioid cell granu-
lomas in many organs. Sarcoidosis is
enerally associated with a low mortality rate (1),
ut cardiac involvement is responsible for more
han two-thirds of the deaths (2–5). Cardiac sar-
oidosis (CS) has a wide spectrum of clinical
anifestations and may frequently present as di-
ated cardiomyopathy (DCM). It has been reported
hat the patients initially diagnosed with end-stage
CM were rediagnosed with CS upon histological
xamination of the resected myocardium after left
entriculoplasty or ventricular assist device implan-
ation (6,7). Some CS patients have been misdiag-
osed with DCM, primarily because of difficulties
n its diagnosis. The mainstay of treatment for
atients with sarcoidosis is systemic corticosteroid if
isease activity is high; corticosteroid that impedes
the formation of granulomas is effective
against most active clinical manifestations
of CS and may halt progression of left
ventricular (LV) dysfunction and improve
LV remodeling and prognosis in CS pa-
tients (8,9). As such, early diagnosis and
determination of disease activity are desir-
able in the treatment of CS.
18F-fluorodeoxyglucose (FDG) has
been shown to accumulate in inflamed
tissues. The molecular targeting approach
using FDG-positron emission tomogra-
phy (PET) has been validated for the
localization of macrophages and granulo-
matous inflammation (10,11). Recent
studies have revealed that FDG-PET un-
er fasting conditions is a promising modality for
dentification of CS; a heterogeneous FDG uptake
n the heart has been reported to be a characteristic
eature of CS (12–14). However, because a diffuse
ptake of FDG in the normal heart and DCM can
lso be observed, it is prudent to compare the
uantitative and qualitative features of FDG uptake
n sarcoidosis patients with and without cardiac
nvolvement, DCM patients, and normal subjects.
E T H O D S
ubjects and study design. Forty-seven subjects were
rospectively enrolled in the present study of FDG-
ET as follows.
ARCOIDOSIS PATIENTS. Twenty-four of the 47
ubjects had systemic sarcoidosis, which was diag-
n
thy
seosed clinically and/or histologically. Twelve of the4 patients with sarcoidosis had cardiac involve-
ent based on guidelines established in 2006 by the
apanese Ministry of Health and Welfare (15)
Table 1). Twelve patients with sarcoidosis had no
ardiac involvement (non-CS).
ONTROL SUBJECTS. Of the 23 control subjects, 8
atients had idiopathic DCM (5 men, 3 women;
ean age: 58.3  7.9 years; range 44 to 66 years)
ased on angiographic and histological information.
atients with ischemic and valvular causes of DCM
ere excluded from this analysis. Clinical informa-
ion for the individual patients is shown in Table 2.
he remaining 15 age-matched healthy control
ubjects (5 men, 10 women; mean age: 57.7  7.5
ears; range 50 to 72 years) were recruited who had
o evidence of active inflammatory, coronary, val-
ular disease; these subjects did not have uncon-
rolled diabetes mellitus or insulin treatment or
evere hepatic, renal, malignant and hematological
iseases and were not receiving corticosteroids.
Table 1. Guidelines for Diagnosis of CS (2006)
Histologic diagnosis group
Cardiac sarcoidosis is conﬁrmed when endomyocardial biopsy
specimens demonstrate noncaseating epithelioid cell
granulomas with histological or clinical diagnosis of
extracardiac sarcoidosis.
Clinical diagnosis group
Although endomyocardial biopsy specimens do not
demonstrate noncaseating epithelioid cell granulomas,
extracardiac sarcoidosis is diagnosed histologically or
clinically and satisﬁes the following conditions and more
than 1 in 6 basic diagnostic criteria.
1. 2 or more of the 4 major criteria are satisﬁed.
2. 1 in 4 of the major criteria and 2 or more of the
5 minor criteria are satisﬁed.
Major criteria
a. Advanced atrioventricular block.
b. Basal thinning of the interventricular septum.
c. Positive 67gallium uptake in the heart.
d. Depressed ejection fraction of the left ventricle (50%).
Minor criteria
a. Abnormal ECG ﬁndings: ventricular arrhythmias
(ventricular tachycardia, multifocal or frequent PVCs),
CRBBB, axis deviation or abnormal Q-wave.
b. Abnormal echocardiography: regional abnormal wall
motion or morphological abnormality (ventricular
aneurysm, wall thickening).
c. Nuclear medicine: perfusion defect detected by
201thallium or 99mtechnetium myocardial scintigraphy.
d. Gadolinium-enhanced CMR imaging: delayed
enhancement of myocardium.
f. Endomyocardial biopsy: interstitial ﬁbrosis or monocyte
inﬁltration over moderate grade.
CMR  cardiac magnetic resonance; CRBBB  complete right bundle branch
block; CS  cardiac sarcoidosis; ECG  electrocardiogram; PVC  prematureB B R E V I A T I O N S
N D A C R O N YM S
OV coefficient of variatio
S cardiac sarcoidosis
CM dilated cardiomyopa
DG 18F-fluorodeoxygluco
a 67gallium
V left ventricular
ET positron emission
omography
UV standardized uptake
alue
c-MIBI 99mTechnetiumventricular contraction.
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1221Serum calcium, C-reactive protein, angiotensin-
onverting enzyme, and B-type natriuretic peptide
evels were measured in all patients. All patients
nderwent chest X-ray, resting 12-lead electrocardio-
ram, transthoracic echocardiography, and 3 types of
Table 2. Clinical Information of All Patients
Age
(yrs) Sex ECG Findings
LV
Thinning
LVEF
(%) (
Sarcoidosis without cardiac involvement
61 F WNL Absent 66
44 M WNL Absent 69
72 F LAH  IRBBB Absent 80
62 F PVC Absent 64
80 F 3rd° AVB, PM Absent 72
27 M WNL Absent 63
56 F WNL Absent 68
54 F WNL Absent 68
28 M ST-T change Absent 70
43 M nsVT Absent 61
79 F PAC, PVC Absent 67
75 F A.Fib, PVC Absent 66
Cardiac sarcoidosis
44 F ST-T change, VT, AICD Present 43
62 M LAH  CRBBB, 1st°
AVB
Absent 77
78 M 3rd° AVB, nsVT, PM,
AICD
Present 32
69 M 3rd° AVB, VT, PM,
AICD
Absent 53
60 F 3rd° AVB, VT, PM,
AICD
Present 65
55 F LAH  CRBBB, PVC Present 36
56 F 3rd° AVB, PVC, PM Absent 62
62 F ST-T change, VT Present 53
53 F ST-T change, PVC Present 40
77 F Wide QRS complex,
nsVT
Present 32
80 F 3rd° AVB, A.Fib, VT,
PM, AICD
Present 51
60 F ST-T change, nsVT Present 60
Idiopathic dilated cardiomyopathy
66 F 3rd° AVB, VT, PM Present 22
62 F A.Fib, ST-T change Absent 49
63 M ST-T change, PAC, VT,
AICD
Absent 40
62 M Wide QRS complex,
VT, AICD
Absent 24
59 M CLBBB, PVC Absent 40
64 M ST-T change, nsVT Absent 29
46 M LAH, ST-T change Absent 33
44 F Transient 3rd° AVB, VT Present 30
ACE  angiotensin-converting enzyme; A.Fib  atrial ﬁbrillation; AICD  auto
peptide; COV  coefﬁcient of variation; CRP  C-reactive protein; Ga  67galliu
left ventricular ejection fraction; Nml  normal; nsVT  nonsustained ventr
99mtechnetium sestamibi; VT  ventricular tachycardia; WNL  within normaladionucleotide imaging using 99mtechnetium sesta- pibi (Tc-MIBI) for myocardial perfusion, 67gallium
Ga), and FDG for whole-body evaluation. All these
valuations were performed within 2 weeks. All sub-
ects gave informed consent. The Ethical Committee
or the Clinical Research of Kurume University ap-
P
l) Tc-MIBI
Ga Uptake
in the Heart
ACE
(IU/L/37°C)
CRP
(mg/dl) COV
1 Nml Negative 15.5 0.07 0.163
6 Nml Negative 42.4 1.03 0.069
3 Nml Negative 23.7 0.21 0.176
3 Nml Negative 15.1 0.11 0.159
5 Nml Negative 30.9 0.06 0.119
4 Nml Negative 18.7 2.71 0.147
1 Nml Negative 9.4 2.64 0.157
4 Nml Negative 33.1 0.04 0.148
5 Nml Negative 19.5 0.23 0.110
5 Nml Negative 16.4 0.13 0.168
9 Nml Negative 25.8 0.05 0.185
0 Nml Negative 20.7 1.18 0.091
5 Hypo Positive 6.2 1.05 0.182
2 Hypo Negative 41.3 0.24 0.200
0 Hypo Positive 14.3 0.08 0.245
1 Hypo Negative 1.1 0.18 0.195
7 Hypo Positive 23.0 0.04 0.302
2 Hypo Positive 22.4 0.30 0.348
4 Hypo Negative 14.4 0.07 0.292
7 Hypo Negative 45.3 0.05 0.205
5 Hypo Negative 26.2 0.14 0.263
8 Hypo Negative 16.0 0.04 0.293
4 Hypo Negative 19.2 0.28 0.226
5 Hypo Negative 45.7 0.13 0.240
5 Hypo Negative 14.9 0.04 0.148
4 Nml Negative 20.0 0.04 0.161
4 Nml Negative 10.3 0.62 0.139
1 Hypo Negative 2.3 0.04 0.171
4 Hypo Negative 9.6 0.04 0.131
2 Hypo Negative 14.6 0.04 0.144
2 Nml Negative 13.2 0.06 0.113
3 Hypo Negative 10.1 0.04 0.162
c implantable cardioverter-deﬁbrillator implanted; AVB  atrioventricular block;
BBB  incomplete right bundle branch block; LAH  left anterior hemiblock; LV
r tachycardia; PAC  premature atrial contraction; PM  permanent pacemak
other abbreviations as in Table 1.BN
pg/m
Number of
Criteria
Major Minor
1 0 0
0 0
2 0 1
4 0 1
5 1 0
0 0
3 0 0
2 0 0
2 0 0
1 0 1
6 0 0
11 0 0
18 3 3
15 1 3
30 4 3
14 1 2
13 3 3
9 3 4
10 1 2
36 1 4
10 2 3
52 2 3
25 2 3
3 1 2
77 — —
64 — —
2 — —
40 — —
20 — —
2 — —
3 — —
8 — —
mati BNP  B-type natriuretic
m; IR  left ventricular; LVEF 
icula er implanted; Tc-MIBI roved this study.
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1222chocardiography. A comprehensive transthoracic
chocardiography examination was performed in all
atients using a standardized approach with an
chocardiograph (Sonos 5500, Philips Medical Sys-
ems, Inc., Bothell, Washington) interfaced with a
ultifrequency megahertz transducer. The LV end-
iastolic and -systolic dimensions were determined
rom M-mode or B-mode echocardiograms. The
V ejection fraction was obtained via the modified
iplane Simpson method. Echocardiographic find-
ngs were blindly evaluated by 2 experienced
ardiologists.
c-MIBI and Ga scintigraphy. All patients underwent
yocardial perfusion imaging with Tc-MIBI and
a scintigraphy for whole-body imaging. Single-
hoton emission computed tomography images of
yocardial perfusion scan at rest was acquired 3 h
fter intravenous injection of Tc-MIBI (740 MBq)
fter at least 12 h of fasting. To remove Tc-MIBI
ccumulation in the gallbladder, all patients drank
ilk 45 min after the tracer injection. 67Gallium
cintigraphic imaging was performed 48 h after
ntravenous injection of Ga citrate (74 MBq) for
hole-body planar and single-photon emission
omputed tomography images. Three experienced
uclear radiologists blindly interpreted the images
ithout knowing their clinical findings. When eval-
ations of the images differed, an agreement was
eached by discussion.
DG-PET. FDG-PET images were acquired after at
east a 12-h period of fasting in order to minimize
he myocardial FDG uptake in all 47 subjects.
lasma glucose levels were measured before the
njection of the tracer. Each subject received an
ntravenous administration of 4.2 MBq of FDG per
ilogram of body weight and had to be kept in a
esting state before PET images were taken. One
our after the FDG injection, PET imaging for
valuation of 3-dimensional heart and whole body
as carried out using a PET scanner (Allegro,
hilips Medical Systems [Cleveland], Inc., Cleve-
and, Ohio). We performed an attenuation correc-
ion for the PET imaging by a rotating rod of
ctivity in the PET scanner. PET imaging was
erformed for review on a workstation (Sun Blade
000, Sun Microsystems, Inc., Santa Clara, Cali-
ornia). The FDG-PET images were visually eval-
ated for the presence of FDG uptake in the heart
n the basis of the agreement of 2 cardiologists
linded to other clinical information and treatment
ssignment of each subject. We classified the FDG-
ET images into 4 patterns, as previously described14), by uptake: “none,” “diffuse,” “focal,” and “focal un diffuse.” To ensure that the regions of FDG
ptake in CS patients correlate with sites of Ga
ptake in the heart, we coregistered the PET
mages with the Ga images. Next, reorientation of
he axial images to a standard cardiac orientation
as undertaken and then the standardized uptake
alue (SUV) was determined. The intensity of
yocardial FDG uptake was quantified by measur-
ng the SUV in all 17 segments followed by a
cientific statement from the American Heart As-
ociation (16). Analysis of myocardial FDG uptake
as performed by recognition of endomyocardial
nd epimyocardial borders and by subdividing the
V in each segment. We determined SUV of each
egment in all 17 segments for each subject and
hen calculated the average of SUV and SD of SUV
or each patient. Thereafter, the coefficient of vari-
tion (COV) of SUV in each patient was calculated
y dividing SD of SUV by average of SUV as an
ndex of heterogeneity of the FDG uptake. Two
uclear radiologists blindly measured SUV, and the
easurements were averaged. The intraobserver
nd interobserver variability of SUV measurements
ere 5%.
valuation for the effect of corticosteroids therapy.
ine of 12 patients with CS were treated with
orticosteroid. Initially, the patients were treated
ith 30 mg/day of prednisolone orally for the first 4
eeks. Then the dose was decreased to 20 mg/day
or the next 4 weeks and maintained at 10 mg/day
hereafter. The other medications were not altered
uring the course of the corticosteroid treatment.
lthough corticosteroid is regarded as the first-line
rug, 3 patients did not receive corticosteroid: 1 had
hronic hepatitis C and the other 2 refused the
reatment. In 9 patients with CS, FDG-PET was
epeated 1, 3, 6, and 12 months later. One un-
reated CS patient underwent FDG-PET 12
onths later.
tatistical analysis. Data were described as mean 
D. Categorical variables were compared by the use
f chi-square analysis. Continuous variables were
ogarithmically transformed if necessary and com-
ared using analysis of variance followed by Scheffe
omparison test between groups. The COV values
t each time point were analyzed by repeated
easures analysis of variance with Scheffe test for
omparisons over a time course. Values of 0.05
ere considered statistically significant. The diag-
ostic performance was analyzed using receiver-
perator characteristic curves, displaying sensitivity
nd specificity at different cutoff values, and the area
nder the curve values were computed.
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1223E S U L T S
aseline characteristics. Characteristics of the 24
atients with systemic sarcoidosis (non-CS: n 12,
S: n 12) and the 8 DCM patients are presented
n Tables 2 and 3. There were no significant
ifferences in age, fasting blood sugar, glycosylated
emoglobin A1C, C-reactive protein, serum cal-
ium, and angiotensin-converting enzyme between
he 3 groups. Female pre-dominance was observed
n patients with systemic sarcoidosis. In non-CS
atients, serum levels of B-type natriuretic peptide
ere lower than those of CS (p  0.01) and DCM
p  0.01) patients. Advanced atrioventricular block
equiring permanent pacemaker was frequent in CS
p  0.11 for trend). The incidence of ventricular
achycardia was similar between CS and DCM. Tc-
IBI abnormalities were common in both CS and
Table 3. Summary of Clinical Variables
Variables (Normal Value)
Non-CS
(n  12)
Age, yrs 56.8 17.6
Age (range), yrs 27–80
Women, n (%) 8 (67)
Cardiothoracic ratio, % 48.1 6.0
Fast blood sugar,† [80–109] mg/dl 95.9 7.4
HbA1C, [4.3–5.8] % 5.39 0.17
BNP,† [18.4] pg/ml 23.5 1.8
CRP, [0.20] mg/dl 0.71 0.95
Serum calcium, [8.7–10.3] mg/dl 9.17 0.26
ACE, [8.3–21.4] IU/ l/37°C 23.2 8.9
LV end-diastolic diameter, mm 48.1 6.3
LV end-systolic diameter, mm 29.9 5.0
LV ejection fraction, % 67.8 4.7
LV wall thinning, n (%) 0 (0)
Advanced AVB, n (%) 1 (8)
Ventricular tachycardia, n (%) 1 (8)
Myocardial perfusion defect, n (%) 0 (0)
Cardiac Ga accumulation, n (%) 0 (0)
Medication use, n (%)
Digitalis 0 (0)
Diuretics 2 (17)
ACE inhibitor 0 (0)
ARB 1 (8)
Beta blockers 0 (0)
Calcium channel blockers 4 (33)
Antiarrhythmic agents 0 (0)
Warfarin 1 (8)
Categorical variables are summarized by frequency and percentage. Continuou
performed with analysis of variance post hoc tests, except categorical variables,
value was used for the calculation of means and SD. ‡p 0.05 versus CS. §p
ARB  angiotensin receptor blockers; CS  cardiac sarcoidosis; DCM  dilated
Table 2.CM. All CS patients, none of the non-CS patients, cnd 5 of 8 (63%) DCM patients exhibited abnormal
yocardial perfusion. According to abnormal myocar-
ial perfusion, the sensitivity and specificity for diag-
osing CS were 100% and 76%, respectively. The
iagnostic accuracy is relatively high, but it is not
pecific to CS and lacks assessment of disease activity.
a scintigraphy, a well-known imaging modality for
iagnosing and assessing disease activity of cardiac
nvolvement, was positive in only 4 of 12 (33%) CS.
All patients were on optimal and stable doses of
igoxin, diuretics, angiotensin-converting enzyme
nhibitors, and/or angiotensin receptor blockers or
eta-blockers. A list of the medications except for
orticosteroid is shown in Table 3.
chocardiographical data. CS patients had lower LV
ystolic function than non-CS patients (p  0.01)
id. DCM patients demonstrated ventricular en-
argement and reduced ejection fraction on echo-
CS
(n  12)
DCM
(n  8)
63.0 10.6 58.3 7.9
44–80 44–66
9 (75) 3 (38)
53.4 4.3 58.0 5.5*
99.0 7.6 103.6 7.9
5.65 0.66 5.46 0.36
160.2 12.3* 123.5 9.5*
0.22 0.27 0.12 0.19
9.83 0.97 9.18 0.30
24.7 14.2 11.9 4.8
53.8 7.3 64.9 9.6*‡
40.0 9.9 54.8 10.5*§
50.3 13.6* 33.3 8.5*‡
9 (75)* 2 (25)
5 (42) 2 (25)
8 (67)* 5 (63)*
12 (100)* 5 (63)*
4 (33) 0 (0)
3 (25) 2 (25)
7 (58) 5 (63)
3 (25) 1 (13)
6 (50) 7 (88)*
2 (16) 5 (63)*
1 (8) 0 (0)
4 (33) 2 (25)
5 (42) 4 (50)
iables are summarized by mean  SD unless otherwise noted. Analyses were
hich chi-square analysis was used. *p  0.01 versus Non-CS. †Log-transformed
versus CS.
iomyopathy; HbA1C  glycosylated hemoglobin A1C; other abbreviations as ins var
for w
0.01
cardardiography (Table 3). Echocardiograph septal
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1224all thinning, a characteristic feature of CS, was
ore frequent in CS (p  0.01 for trend).
DG-PET image. The FDG uptake in the heart was
ighly variable in all subjects. Representative FDG-
ET anterior views of maximum intensity projec-
ion are demonstrated in Figure 1: panels A, C, E,
show low myocardial uptake and panels B, D, F,
demonstrate high myocardial uptake. In control
ubjects, non-CS patients, and DCM patients, the
ptake was predominantly homogeneous; minor
eterogeneity, if seen, did not contribute to signif-
cant COV. On the other hand, the uptake ap-
eared distinctly heterogeneous in CS patients with
igh COV, regardless of the magnitude of FDG
ptake (SUV). In addition, distinct FDG uptake
as observed in hilar and mediastinal lymph in
arcoidosis patients regardless of cardiac involve-
ent. The result obtained from coregistration of
ET and Ga images clearly demonstrated that the
Figure 1. Representative FDG-PET Anterior Views
The myocardial uptake of FDG in healthy control subjects (A,B), non
myopathy (G,H) patients. COV  coefﬁcient of variation; CS  card
oxyglucose; PET  positron emission tomography; SUV  standardegions of FDG uptake closely correlated with slmost all sites of Ga uptake in the heart (Fig. 2).
s previously reported (14), all CS patients
howed myocardial FDG uptake. Also, the dif-
use FDG uptake on PET images was not seen.
mong the 15 controls, 1 (7%), 4 (27%), 1 (7%),
nd 9 (60%) individuals exhibited none, diffuse,
ocal, and focal on diffuse patterns, respectively.
lso, there were 5 (42%) non-CS patients and 4
50%) DCM patients showing the focal on diffuse
ptake. When we utilized the presence of “focal”
nd “focal on diffuse” uptakes for diagnosis of CS
sing FDG-PET images as described previously,
he sensitivity and specificity of the feature for
iagnosing CS were 100% and 34%, respectively.
t is noteworthy that there were many false
ositive results confirmed to be CS by “focal on
iffuse” finding on FDG-PET.
The quantitative analysis of FDG uptake in
yocardium revealed that the average of SUV was
diac sarcoidosis (C,D), cardiac sarcoidosis (E,F), and dilated cardio-
arcoidosis; DCM  dilated cardiomyopathy; FDG  18F-ﬂuorode-
uptake value.car
iac similar among all subject groups (Fig. 3A). Al-
t
t
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1225hough SD of SUV was greater in CS than that of
he other subject groups, it was not statistically
ignificant between CS and DCM (Fig. 3B). We
S
Ga
Planar
Coronal
Sagittal
Transverse
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1226reater in CS patients (0.25 0.05) than in control
ubjects (0.14  0.03, p  0.01), non-CS patients
0.14  0.03, p  0.01), or DCM patients (0.15 
.02, p  0.01). The cutoff COV value for the
iagnosis of CS was computed as 0.18 with sensi-
ivity of 100% and specificity of 97% by the
eceiver-operator characteristic curve.
orticosteroid treatment. Corticosteroid treatment
as initiated in 9 of 12 patients with CS; the
emaining 3 CS patients had not received cortico-
teroid treatment. One-year corticosteroid treat-
ent prevented deteriorations of LV remodeling
LV end-diastolic diameter from 53.4  7.8 mm to
6.8 6.8 mm, p 0.33) and LV systolic function
LV ejection fraction from 53.0  12.6% to 55.6 
3.7%, p  0.90). Representative FDG-PET im-
ges are shown in Figure 4 from a patient who took
orticosteroid and 1 who did not. There was almost
complete resolution of heterogeneity after corti-
osteroid therapy. On the other hand, heterogeneity
urther increased without corticosteroid treatment.
he pooled data of COV in 9 CS patients 1 month
fter corticosteroid therapy showed a significant
ecrease in FDG uptake from 0.24  0.05 to
.14  0.06 (p  0.05); FDG uptake remained low
Figure 4. Follow-Up FDG-PET Scans at 1 Year in CS Patients
Serial FDG–positron emission tomography scan after corticosteroid
dial FDG uptake (A), whereas more heterogeneous myocardial FDG
costeroids; other abbreviations as in Figure 1.hroughout the 12-month follow-up (Fig. 5). Thereere 3 patients, 2 non-CS and 1 CS, without
orticosteroid treatment who underwent repeated
DG-PET scans 1 year after. The COV value of 1
S patient without steroid therapy increased from
apy revealed complete resolution of the heterogeneity of myocar-
ake was seen in an untreated patient after 1 year (B). Rx  corti-
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Figure 5. The Time Course of COV
Dark green circles indicate mean  SD changes in COV of maxi-
mum SUV in 9 cardiac sarcoidosis patients from baseline to 12
months after corticosteroid therapy. The orange squares indicate
the COV value in 2 noncardiac sarcoidosis in baseline and
12-month follow-up FDG–PET. The light green circles indicate the
COV value in a cardiac sarcoidosis patient not treated with cortico-
steroid in baseline and 12-month follow-up FDG–positron emissionther
upttomography. Abbreviations as in Figure 1.
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1227.30 to 0.39, indicating worsening of disease activ-
ty (Fig. 5). In 2 non-CS patients, it appeared to be
eproducible from 0.16 to 0.14, suggesting a poten-
ial role for serial testing (Fig. 5).
I S C U S S I O N
he FDG uptake was distinctly heterogeneous in
S patients. Coefficient of variation, an index of
eterogeneity of FDG uptake, emerged as a useful
arker of CS and active myocardial inflammation.
n DCM, the COV was comparable to non-CS and
ealthy control subjects.
FDG is a synthetic tracer that mimics the bio-
hemical behavior of the natural glucose molecule.
ecause normal myocardium uses free fatty acids as
he energy source under resting physiologic condi-
ions in the fasting state, FDG uptake into the
ormal heart is expected to be low. However, some
ealthy subjects demonstrate higher FDG uptake
ased on various factors, such as dietary habits, old
ge, obesity, and glycemic state. In this study, we
id not find a significant correlation between FDG
ptake and age, body mass index, or blood glucose
evels in control subjects. In fact, we excluded
ubjects with blood glucose 120 mg/dl. The wide
isparity of FDG uptake in the normal heart has
lso been reported previously (17,18). The FDG
ptake in DCM was similar to that in healthy
ontrol subjects, suggesting no diagnostic usefulness
f the average of FDG uptake for DCM. Whenever
resent, myocardial glucose utilization was nor-
ally expected to be homogeneous in the normal
ontrols. However, SD of SUV slightly varied in
ontrol subjects (Fig. 3B), a large spatial and tem-
oral heterogeneity of the myocardial metabolic
attern has been previously reported in subjects
ithout heart disease (17), and FDG uptake in the
ateral LV wall has been shown to be high (19,20).
he heterogeneity of myocardial glucose metabo-
ism in the normal human heart may be related to
egional substrate availability. Caution should be
xercised in the interpretation of SD of SUV
ecause it is dependent on total FDG uptake. As
uch, we calculated COV of SUV in each patient by
ividing SD of SUV by average of SUV as an index
f heterogeneity of the FDG uptake. The COV in
ontrol subjects was low and relatively constant,
hich is indicative of homogenous uptake of FDG
n the normal heart.
In CS patients, the COV was significantly high
ompared to that of control subjects, indicating
eterogeneous uptake of FDG. In CS, FDG uptake sn some regions of the heart may be decreased due
o myocardial fibrosis, whereas it may be increased
n other regions due to inflammatory granulomas.
oefficient of variation in CS patients was not only
igh but also distinctly different from that of
ontrol subjects and non-CS patients. The high
OV in CS patients indicates the presence of active
nflammation because the high COV prior to ste-
oid treatment decreased to the level of healthy
ontrol subjects after treatment; FDG uptake also
esolved in the hilar and mediastinal lymph nodes
fter steroid treatment. A high heterogeneous FDG
ptake in DCM should also be possible due to
yocardial cell loss or regional fibrosis. In fact,
ccasionally images did appear to demonstrate some
eterogeneity in FDG uptake (Fig. 1H). However,
OV in DCM was not high and comparable to
hat in controls, which suggests that interstitial
brosis alone without active inflammation may not
uffice for distinct FDG heterogeneity. Beta-
lockers may also affect regional FDG uptake
21,22), but the COV in DCM patients receiving
eta-blockers (0.15  0.01) was similar to that of
atients not receiving beta-blockers (0.14  0.02,
 0.49). Visual inspection gave us an impression
f heterogeneous uptake of FDG infrequently in
CM, but the COV was always below 0.18 and
omparable to control subjects. The visual impres-
ion of heterogeneity in DCM is reflected by SD
Fig. 3B), which was high in some cases.
Heterogeneous uptake of FDG into the heart,
herefore, is diagnostic of CS. However, because
eterogeneity is dependent on the total myocardial
DG uptake, the heterogeneity index, COV
0.18, provides a high sensitivity and specificity for
iagnosis of CS. Also, COV is useful for monitor-
ng the response to corticosteroid treatment.
tudy limitations. There are some obvious limita-
ions in the present study. First, the small study size
imits our interpretation and discussion. In addi-
ion, single-center data limits the generalizability of
ur findings by its selection bias. With regard to
election bias, we cannot exclude the possibility of
nknown confounders. Second, we did not ran-
omize patients with or without the use of cortico-
teroids and were not able to judge clinical benefits
f corticosteroids from this study. Although atrial
brillation and left bundle branch block are re-
orted to affect the regional glucose utilization
23,24), the small sample size does not allow such
nalysis. Future investigations with a larger study
ize are needed to address these issues.
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1228O N C L U S I O N S
eterogeneous uptake in the heart on FDG-PET
s highly suggestive of CS, but a quantitative eval-
ation is necessary, especially for differential diag-
osis from DCM. The heterogeneous uptake in the
eart in CS may disappear as early as 1 month after
he corticosteroid therapy.
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